Construction of protein binding sites in scaffold structures.
We have developed a strategy for grafting a protein-protein interface based on the known crystal structure of a native ligand and receptor proteins in a complex. The key interaction residues at the ligand protein binding interface are transferred onto a scaffold protein so that the mutated scaffold protein will bind the receptor protein in the same manner as the ligand protein. First, our method identifies key residues and atoms in the ligand protein, which strongly interact with the receptor protein. Second, this method searches the scaffold protein for combinations of candidate residues, among which the distance between any two candidate residues is similar to that between relevant key interaction residues in the ligand protein. These candidate residues are mutated to key interaction residues in the ligand protein respectively. The scaffold protein is superposed onto the ligand protein based upon the coordinates of corresponding atoms, which are assumed to strongly interact with the receptor protein. Complementarity between scaffold and receptor proteins is evaluated. Scaffold proteins with a low superposing rms difference and high complementary score are accepted for further analysis. Then, the relative position of the scaffold protein is adjusted so that the interfaces between the scaffold and receptor proteins have a reasonable packing density. Other mutations are also considered to reduce the desolvation energy or bad steric contacts. Finally, the scaffold protein is cominimized with the receptor protein and evaluated. To test the method, the binding interface of barstar, the inhibitor of barnase, was grafted onto small proteins. Four scaffold proteins with high complementary scores are accepted.
Liang
S
S
Institute of Physical Chemistry, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, the People's Republic of China.
Liu
Z
Z
Li
W
W
Ni
L
L
Lai
L
L
D001407:Bacillus / Q000737:chemistry; D001426:Bacterial Proteins / Q000737:chemistry / Q000378:metabolism; D001665:Binding Sites; D003198:Computer Simulation; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000378:metabolism; D008024:Ligands; D046911:Macromolecular Substances; D008956:Models, Chemical; D008958:Models, Molecular; D011485:Protein Binding / Q000187:drug effects; D011506:Proteins / Q000737:chemistry* / Q000378:metabolism*; D012260:Ribonucleases / Q000737:chemistry / Q000378:metabolism; D012997:Solvents / Q000494:pharmacology; D013816:Thermodynamics
D001426:Bacterial Proteins; D004791:Enzyme Inhibitors; D008024:Ligands; D046911:Macromolecular Substances; D011506:Proteins; D012997:Solvents; C057438:barstar protein, Bacillus amyloliquefaciens; D012260:Ribonucleases; C019760:Bacillus amyloliquefaciens ribonuclease